Cyclo Therapeutics Inc Stock Ownership - Who owns Cyclo Therapeutics?


Insider buying vs selling

Have Cyclo Therapeutics Inc insiders been buying or selling?
Francis Patrick OstronicDirector2022-09-215,000$1.76
Francis Patrick OstronicDirector2022-05-204,988$2.04
Francis Patrick OstronicDirector2022-05-2012$2.00
Jeffrey TateChief Operating Officer2022-05-163,000$2.12
Jeffrey TateChief Operating Officer2022-04-29300$2.70
Jeffrey TateChief Operating Officer2022-04-291,065$2.71
Jeffrey TateChief Operating Officer2022-04-28635$2.50
Francis Patrick OstronicDirector2022-04-065,000$2.90
Markus SiegerDirector2022-03-2910,000$2.73
N. Scott FineChief Executive Officer2022-02-0710,334$3.58

1 of 3

CYTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CYTH insiders and whales buy or sell their stock.

CYTH Shareholders

What type of owners hold Cyclo Therapeutics Inc stock?
Armistice Capital LLC374.33%31,591,538$53.90MInsider
Novit LP254.96%21,517,582$36.71MInsider
Ce Rick Strattan236.24%19,937,647$34.01MInsider
George L. Fails19.97%1,685,221$2.87MInsider
Joseph J. Farnan Jr.15.88%1,340,000$2.29MInsider
Vanguard Group Inc3.01%253,765$432.92kInstitution
Francis Patrick Ostronic1.79%150,687$257.07kInsider
N. Scott Fine1.72%145,000$247.37kInsider
Markus Sieger1.09%91,674$156.40kInsider
Renaissance Technologies LLC0.76%63,986$109.16kInstitution

1 of 3

CYTH vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CYTH0.52%99.48%Net BuyingNet Buying
PLXP27.55%25.72%Net Buying
SBFM3.90%0.82%Net Selling

Cyclo Therapeutics Stock Ownership FAQ

Who owns Cyclo Therapeutics?

Cyclo Therapeutics (NASDAQ: CYTH) is owned by 4.77% institutional shareholders, 908.50% Cyclo Therapeutics insiders, and 0.00% retail investors. Armistice Capital LLC is the largest individual Cyclo Therapeutics shareholder, owning 31.59M shares representing 374.33% of the company. Armistice Capital LLC's Cyclo Therapeutics shares are currently valued at $53.90M.

If you're new to stock investing, here's how to buy Cyclo Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.